Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

DA-020

Small molecule

AApplied Biology, Inc.

DA-020 is one of 22 small molecule programs targeting Alopecia. It is currently in development.

1

Indications

2

Total Trials

2

Active Trials

21

Competitors

Pipeline

Status by Indication[3][1]

Indication

AlopeciaActive, not recruiting

AlopeciaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

40 competitors in Alopecia

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Otezla

Zolymbus

Opzelura

Olumiant

Raptiva

Anzupgo

Alnylam Pharmaceuticals

Cosentyx

Avodart

Akero Therapeutics

Rogaine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

Study completion

NCT07402330

Phase 1/2Not yet recruiting

Alopecia

NCT07397325

Clinical

Trials by Indication[1]

Alopecia1 trial

Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia

Not yet recruiting·AApplied Biology, Inc.·Phase 1/2·NCT07397325·60 enrolled

Unspecified1 trial

Pharmacokinetic Study of DA-020

Not yet recruiting·AApplied Biology, Inc.·Phase 1·NCT07402330·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for DA-020. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DA-020 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DA-020. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Applied Biology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: AApplied Biology, Inc.

Related News